Boehringer Ingelheim sells U.S. injectable generics business and ANDAs to Hikma Pharmaceuticals

Client(s) Boehringer Ingelheim GmbH

Jones Day advised Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies, on the antitrust aspects of two transactions with Jordan based Hikma Pharmaceuticals plc. Most recently, we advised Boehringer on the sale to Hikma of 49 Ben Venue abbreviated new drug applications (ANDAs), which are submitted to the U.S. Food and Drug Administration for generic drug approval. We also advised Boehringer on the sale to Hikma of the assets of Bedford Laboratories, Ben Venue's U.S. injectable generics business, a $300 million deal that closed in July 2014.